BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Alzheimer's Drug Discovery Foundation to Host 12th International Conference on Alzheimer's Drug Discovery


8/22/2011 11:13:47 AM

NEW YORK, Aug. 22, 2011 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation will host the 12th International Conference on Alzheimer's Drug Discovery on September 26-27, 2011 at the Hyatt Regency in Jersey City, New Jersey. The purpose of the conference is to bring together investigators intent on accelerating the development of treatments for Alzheimer's disease and related dementias. The Alzheimer's Drug Discovery Foundation's funded investigators and other scientists in the field will present their current research and create opportunities for networking. This annual meeting attracts over 160 academic, industry and government scientists from around the world.

This two-day global meeting is organized around four sub-topics: Targeting Tau for Alzheimer's Disease and Related Dementia; Inflammation, Chaperones and Novel Targets; Neuroprotection and Synaptic Enhancement; and Accelerating Clinical Trials for Alzheimer's Disease Through Biomarkers.

"This year's conference is particularly timely," said Dr. Howard Fillit, ADDF's Executive Director. "We are especially excited about the inclusion of the Accelerating Clinical Trials for Alzheimer's Disease Through Biomarkers section in this year's program. With advances in basic science and experimental research rapidly bringing drug discovery closer to the clinic, it is more important than ever before to foster dialogue between preclinical and clinical researchers in the field and accelerate the translation of new knowledge to patients."

FOR CONFERENCE DETAILS AND TO REGISTER, please visit the conference website. Group discounts are available!

TO CO-SPONSOR OR EXHIBIT, please contact Filomena Machleder at fmachleder@alzdiscovery.org.

About the Alzheimer's Drug Discovery Foundation (ADDF)
The ADDF (www.alzdiscovery.org) is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's Disease, related dementias and cognitive aging. Since 1998, the ADDF has granted more than $45 million to fund over 325 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 18 countries.

SOURCE Alzheimer's Drug Discovery Foundation



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES